<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037513</url>
  </required_header>
  <id_info>
    <org_study_id>67933</org_study_id>
    <secondary_id>R34DA053140</secondary_id>
    <nct_id>NCT05037513</nct_id>
  </id_info>
  <brief_title>Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky</brief_title>
  <official_title>Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hilary L Surratt, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this study is to adapt and feasibility test an evidence-based&#xD;
      strengths-based case management (SBCM) intervention for pre-exposure prophylaxis (PrEP)&#xD;
      initiation, and examine preliminary efficacy of the intervention comparators (SBCM-PrEP) and&#xD;
      (Centers for Disease Control (CDC)-PrEP). Within this context, the Specific Aims are to: 1)&#xD;
      Assess client, provider, organization, and structural-level facilitators and barriers to&#xD;
      integration of a PrEP focused SBCM (SBCM-PrEP) intervention into routine syringe service&#xD;
      program (SSP) practice; 2) Adapt an evidence-based SBCM protocol to provide PrEP intervention&#xD;
      services for people who inject drugs (PWID) in SSP sites; and, 3) Examine feasibility,&#xD;
      acceptability and preliminary efficacy of the adapted SBCM-PrEP. 80 participants will be&#xD;
      randomized into: CDC-PrEP (an in-use PrEP intervention based on CDC guidelines) or SBCM-PrEP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants initiating PrEP</measure>
    <time_frame>3 months post-baseline</time_frame>
    <description>Documented PrEP initiation, measured by dispensed PrEP prescription.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants initiating PrEP</measure>
    <time_frame>6 months post-baseline</time_frame>
    <description>Documented PrEP initiation, measured by dispensed PrEP prescription.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Intervention Engagement assessed by session checklist</measure>
    <time_frame>8 weeks post-baseline</time_frame>
    <description>5 item Session Checklist completed by Nurse-Interventionist post-session; range is 0-15, higher scores are higher engagement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Intervention Satisfaction assessed by the IAQ</measure>
    <time_frame>8 weeks post-baseline</time_frame>
    <description>8 item Intervention Acceptability Questionnaire (IAQ) completed by participants post-intervention; range is 0-32, higher scores are higher satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>CDC-PrEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 session PrEP education following CDC guidelines delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBCM-PrEP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-session Strengths-Based Case Management intervention adapted for PrEP related educational content delivered one on one by an Advanced Practice Registered Nurse to individual clients in the syringe service program setting</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SBCM-PrEP</intervention_name>
    <description>Multi-session SBCM intervention adapted for PrEP initiation focus</description>
    <arm_group_label>SBCM-PrEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CDC-PrEP</intervention_name>
    <description>1 session PrEP education following CDC guidelines</description>
    <arm_group_label>CDC-PrEP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older;&#xD;
&#xD;
          -  HIV-negative status;&#xD;
&#xD;
          -  Past month drug injection;&#xD;
&#xD;
          -  Client of SSP in targeted sites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ HIV-positive status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilary L Surratt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Hilary L Surratt, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

